Pfizer
Pfizer's $11-bn share repurchase ends chances of renewed bid for AstraZeneca
25 Oct 2014
US drugmaker Pfizer’s board yesterday authorised a new $11-billion share repurchase plan, which analysts say puts an end to speculations that it would renew its bid for British rival AstraZeneca
Pfizer’s anti-smoking drug Chantix to carry black-box waning till availability of study data
17 Oct 2014
US judge upholds Ranbaxy-Pfizer Lipitor marketing deal
13 Sep 2014
In a piece of good news for the US FDA-challenged Ranbaxy laboratories, a US court has dismissed an anti-trust suit against Pfizer Inc and India's Ranbaxy that accused them of conspiring to delay sales of generic versions of the cholesterol drug Lipitor
Pfizer hit with lawsuits over Lipitor
11 Aug 2014
Collectis shares surge on Pfizer deal
19 Jun 2014
Pfizer drops AstarZeneca take over bid
28 May 2014
AstraZeneca rejects Pfizer’s third takeover offer
19 May 2014
AstraZeneca said that Pfizer’s tax-driven inversion structure, which is a key part of its proposal, has already been the subject of intense public and governmental scrutiny
Pfizer seeks to allay fears over AstraZeneca deal
07 May 2014
Pfizer says the merger with AstraZeneca would bolster innovative science and speed up the development of new treatments
Cable admits Pfizer-AstaraZeneca deal involves ‘national interest’ issues
05 May 2014
Britain’s Business Secretary Vince Cable said late on Sunday that the bid by Pfizer Inc for AstraZeneca Plc raised questions of “overriding national interest”, as the opposition Labour Party stepped up its campaign against the proposed takeover
AstraZeneca rejects Pfizer’s revised $106 billion offer
02 May 2014
Today’s 50 pounds ($84.47) a share indicative offer followed AstraZeneca's decision to reject an earlier proposal that valued it at 46.61 pounds per share
AstraZeneca to consider Pfizer’s $106-bn bid
02 May 2014
The announcement comes just days after AstraZeneca Plc denied plans to discuss any partnership proposals with Pfizer
Pfizer confirms AstraZeneca's rejection; to explore options
28 Apr 2014
US drugs giant Pfizer today confirmed that it had made a $98.67 billion (£58.73 billion) takeover offer for AstraZeneca, which was rejected by the UK-based company
Pfizer weighs $101-bn bid for AstraZeneca
21 Apr 2014
A potential deal with AstraZeneca would be the biggest-ever acquisition in the pharmaceutical industry, and would see another iconic British brand being acquired by a foreign company
Teva, Sun Pharma to pay Pfizer $2.15 bn to settle patent suit
12 Jun 2013
Teva, the world’s largest generic drug firm, will pay $1.6 billion of the settlement amount while Sun Pharmaceuticals will pay the remaining $550 million
Featured articles
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation
.jpg "Microsoft, Google challenge Delhi HC order to remove non-consensual content")
